Imunon (IMNN) Price & Analysis

Compare

1,357 Followers

IMNN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.83 - $41.22

Previous CloseN/A

Volume151.93K

Average Volume (3M)360.57K

Market Cap

$15.74M

Enterprise Value$11.79M

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$1.19B

Price to Earnings (P/E)―

Beta-0.40

Next Earnings

Nov 17, 2025

EPS Estimate

-1.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.87

Shares Outstanding2,192,353

10 Day Avg. Volume457,759

30 Day Avg. Volume360,569

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)3.26

Price to Sales (P/S)0.00

P/FCF Ratio-0.73

Enterprise Value/Market Cap0.75

Enterprise Value/Revenue16.22

Enterprise Value/Gross Profit-499.69

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$210.00

Price Target Upside2824.79% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessIMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.

Financial StabilityImunon has secured near-term financing through a private placement, providing essential capital needed to cover initiation-related costs of the OVATION study.

Regulatory BenefitsIMNN-001 has orphan status in the US and EU, providing regulatory benefits and market exclusivity.

Bears Say

Funding UncertaintyThe company is in active discussions with potential partners to secure essential capital for the Phase 3 OVATION 3 study.

Trial ComplexityThe trial is set to enroll approximately 500 women with ovarian cancer and will be a broad trial including both BRCA+/HRD and BRCA-/HRP patients.

Imunon News

Imunon sees cash runway into 4Q25

As of June 30, 2025, cash and cash equivalents were $4.7 million. During July 2025, the Company received...

7d ago

IMNN

Imunon reports Q2 EPS ($2.15), consensus ($4.99)

“IMUNON (IMNN) continues to make significant progress in advancing its mission to transform cancer treatment,” said Stacy Lindborg,...

7d ago

IMNN

Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001

IMUNON (IMNN) announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study...

13d ago

IMNN

Imunon board approves 15% stock dividend

IMUNON’s (IMNN) Board of Directors approved a 15% stock dividend, 0.15 shares of common stock per share of...

15d ago

IMNN

Celsion trading halted, news pending

19:50 EDT Celsion trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving...

18d ago

IMNN

Imunon announces 1-for-15 reverse split ratio

IMUNON (IMNN) announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per...

20d ago

IMNN

Imunon, Inc. Advances Cancer Treatment with Phase 3 Trial of IMNN-001

Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Imunon, Inc. is conducting a Phase 3...

14h ago

IMNN

IMUNON, Inc. Reports Progress in Cancer Therapy

Imunon, Inc. ( ($IMNN) ) has released its Q2 earnings. Here is a breakdown of the information Imunon,...

6d ago

IMNN

Imunon, Inc. Earnings Call Highlights Progress and Challenges

Imunon, Inc. (($IMNN)) has held its Q2 earnings call. Read on for the main highlights of the call....

6d ago

IMNN

IMNN Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Imunon, Inc. (IMNN) is scheduled to report 2nd quarter earnings on 08/05/2025, before the market opens. Regarding Q2...

9d ago

IMNN

Imunon Announces 15% Stock Dividend Approval

Imunon ( ($IMNN) ) just unveiled an announcement. On July 28, 2025, IMUNON, Inc. announced a 15% stock...

15d ago

IMNN

Imunon, Inc. Advances DNA Vaccine Study for COVID-19 Variants

Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Imunon, Inc. recently updated its clinical study...

18d ago

IMNN

Imunon, Inc. Advances COVID-19 Vaccine Research with IMNN-101 Study Completion

Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Study Overview: Imunon, Inc. has completed a...

20d ago

IMNN

Imunon Announces Reverse Stock Split to Meet Nasdaq Rules

Imunon ( ($IMNN) ) has shared an announcement. On July 21, 2025, IMUNON, Inc. announced a one-for-fifteen reverse...

20d ago

IMNN

IMNN FAQ

What was Imunon’s price range in the past 12 months?

Imunon lowest stock price was $4.83 and its highest was $41.22 in the past 12 months.

What is Imunon’s market cap?

Imunon’s market cap is $15.74M.

When is Imunon’s upcoming earnings report date?

Imunon’s upcoming earnings report date is Nov 17, 2025 which is in 97 days.

How were Imunon’s earnings last quarter?

Imunon released its earnings results on Aug 05, 2025. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$4.141 by $2.271.

Is Imunon overvalued?

According to Wall Street analysts Imunon’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Imunon pay dividends?

Imunon does not currently pay dividends.

What is Imunon’s EPS estimate?

Imunon’s EPS estimate is -1.48.

How many shares outstanding does Imunon have?

Imunon has 2,192,353 shares outstanding.

What happened to Imunon’s price movement after its last earnings report?

Imunon reported an EPS of -$1.87 in its last earnings report, beating expectations of -$4.141. Following the earnings report the stock price went down -4.75%.

Which hedge fund is a major shareholder of Imunon?

Currently, no hedge funds are holding shares in IMNN

Imunon Stock Smart Score

Underperform

Fundamentals

Return on Equity

-491.97%

Trailing 12-Months

Asset Growth

-9.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imunon

Imunon, Inc. (IMNN) is a biotechnology company focused on the development and commercialization of innovative therapies that leverage its proprietary platform technologies. The company's primary areas of focus include oncology and infectious diseases, with a core emphasis on developing advanced DNA-based immunotherapies and vaccine solutions. Imunon aims to address unmet medical needs by providing effective and safe treatment options for patients worldwide.

Imunon (IMNN) Earnings & Revenues

Historic Earnings Reports

IMNN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects significant progress in clinical trials and strong cost management but is tempered by challenges in capital raising and dependency on partnerships for funding. The positive outcomes in the OVATION 2 study and rapid activation of the OVATION 3 trial are promising, although financial and listing compliance issues pose notable risks.View all IMNN earnings summaries

IMNN Stock 12 Month Forecast

Average Price Target

$210.00

▲(2824.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","110":"$110","211":"$211","59.5":"$59.5","160.5":"$160.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$210.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$210.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$210.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,59.5,110,160.5,211],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.74,46.37538461538462,60.01076923076923,73.64615384615385,87.28153846153846,100.91692307692307,114.55230769230769,128.18769230769232,141.8230769230769,155.45846153846153,169.09384615384616,182.72923076923078,196.36461538461538,{"y":210,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.74,46.37538461538462,60.01076923076923,73.64615384615385,87.28153846153846,100.91692307692307,114.55230769230769,128.18769230769232,141.8230769230769,155.45846153846153,169.09384615384616,182.72923076923078,196.36461538461538,{"y":210,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.74,46.37538461538462,60.01076923076923,73.64615384615385,87.28153846153846,100.91692307692307,114.55230769230769,128.18769230769232,141.8230769230769,155.45846153846153,169.09384615384616,182.72923076923078,196.36461538461538,{"y":210,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.91,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.17,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.09,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.54,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.76,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >